Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dareen Siri

Allergy & Immunology Normal, IL Medical Doctor

NPI 1730272998 CMS profile 33612

2010 Jacobssen Dr, Normal, IL 61761

Open in the dashboard

General payments

$1,496,506

2,090 records reported · program years 2019–2025

Research payments

$27,567

Paid to them · 42 records reported · program years 2019–2025

Ownership & investment interest

$68,475

2 holdings reported · through program year 2025

Research they led as principal investigator

$4,393,616 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Dareen Siri of Normal, IL is reported in the CMS Open Payments database as having received $1,496,506 across 2,090 general payments and $27,567 in research payments paid to them. Separately, studies naming them as principal investigator received $4,393,616 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $68,475 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $376,990 406
2024 General $234,820 320
2024 Research $4,750 1
2023 General $202,970 272
2023 Research $22,817 41
2022 General $258,274 323
2021 General $134,725 221
2020 General $109,402 196
2019 General $179,324 352
2025 Ownership $34,238 1
2024 Ownership $34,238 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dareen Siri
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Dareen Siri were reported at $376,990. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Dareen Siri Allergy & Immunology median Middle half National median
2019 $179,324 $378 $115–$1,178 $163
2020 $109,402 $303 $75–$1,581 $114
2021 $134,725 $407 $122–$1,475 $132
2022 $258,274 $357 $120–$1,340 $149
2023 $202,970 $445 $124–$1,536 $160
2024 $234,820 $541 $129–$1,763 $164
2025 $376,990 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $305,834 365 payments
  2. Genzyme Corporation $200,894 183 payments
  3. AbbVie, Inc. $180,778 173 payments
  4. GlaxoSmithKline, LLC. $157,756 238 payments
  5. OptiNose US, Inc. $117,419 174 payments
  6. Pharming Healthcare, Inc. $106,801 149 payments
  7. ADMA BioManufacturing LLC $61,133 74 payments
  8. Incyte Corporation $46,545 51 payments
  9. Aimmune Therapeutics, Inc. $32,800 14 payments
  10. Novartis Pharmaceuticals Corporation $30,030 42 payments
  11. Other $256,515 627 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $754,877 306 payments
  2. Consulting Fee $406,400 151 payments
  3. Travel and Lodging $168,014 432 payments
  4. Honoraria $118,489 56 payments
  5. Food and Beverage $48,187 1,121 payments
  6. Education $540 24 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $181,809 158 payments
  2. RINVOQ $167,780 158 payments
  3. DUPIXENT Inflammation And Immunology $166,119 226 payments
  4. Xhance $117,419 174 payments
  5. DUPIXENT Immunology And Inflammation $115,712 117 payments
  6. RUCONEST $100,116 142 payments
  7. NUCALA Immunology $81,119 86 payments
  8. NUCALA Respiratory $56,344 64 payments
  9. PALFORZIA $32,800 14 payments
  10. OPZELURA $31,037 48 payments
  11. Other $228,891 723 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ADMA BioManufacturing LLC $21,783 34 payments
  2. Consortium of Independent Immunology Clinics, LLC $4,750 1 payment
  3. GlaxoSmithKline, LLC. $1,034 7 payments

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

229

Median for Allergy/ Immunology: 449

Drug cost

$264,566

Median for Allergy/ Immunology: $169,700

Branded share of claims

63.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 41 $152,911
Cinqair Reslizumab Brand 12 $51,889
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 63 $45,976
Xhance Fluticasone Propionate Brand 17 $11,732
Azelastine Hcl Generic 33 $1,303
Montelukast Sodium Generic 51 $515
Albuterol Sulfate Hfa Albuterol Sulfate Brand 12 $241

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$142,669

Of which drugs: $99,021

Medicare patients

158

Average age 72

Services billed

9,281

88 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 46%
Ischemic heart disease 28%
COPD 25%
Diabetes 22%
Chronic kidney disease 15%
Depression 15%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$78,410 41 —
RINVOQ
$26,753 — —
RUCONEST
$24,117 — —
VTAMA
$17,633 — —
TAPINAROF
$12,013 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

2,132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record